Indianapolis, IN (PRWEB) August 26, 2011
“Medical care providers and patients with neuroendocrine cancer will hear things at this conference that can change lives,” according to Bob Wahmann, spokesperson for CCAN, a non-profit group that promotes awareness of neuroendocrine (NET) cancer. "We’re teaming with the Indy Carcinoid Awareness Network to produce the 2011 Indy NET Cancer Patient Conference, taking place in Indianapolis at the Hyatt Regency, State Capitol on September 17th. It’s the perfect opportunity to learn from some of the foremost experts in the world: Dr. Thomas O’Dorisio, Dr. Eugene Woltering, Dr. Lowell Anthony, Dr. Phil Boudreaux and Dr. Aaron Vinik."
Discover -AHEAD of the rest of the US- a cutting edge new development in personalized medicine. Dr. Thomas O’Dorisio will introduce “Theranostics- “Molecular targeting of VECTORS which can be used for both therapies and diagnosis …(it) embodies both molecular and personalized medicine.” This new Field was introduced by Professor Richard Baum from Bad Berka, Germany at the World Congress. Other topics: ‘Prioritizing Treatment Options for NET Cancer Patients’ -- ‘The Role of Surgery In NET Cancer’ -- ‘Neuroendocrine Tumors: Recognition & Potential New Therapies’ -- ‘Options of Care & the Value of Tumor Markers’ -- ‘Evaluation & Treatment Of Pancreatic NETS’
Wahmann goes on to explain, “The faculty and the topics being covered at this event are absolutely astounding. These conferences need to be affordable so we only charge a small commitment fee. The full day event includes presentations by 5 neuroendocrine cancer experts, a question & answer panel, lunch and networking. ‘A Rare Affair’ Fundraiser will be held the evening before the conference to raise much needed funds to continue awareness and research projects. Appetizers, wonderful desserts, wines, entertainment and more surround a silent auction fundraiser.
Who Should Attend?
Doctors, nurses, physician’s assistants, patients- anyone who might be in a position to suspect, diagnose, treat and help carcinoid / NET cancer patients. Medical professionals can join the North American NeuroEndocrine Tumor Society (NANETS.) The purpose of this professional organization is to improve NET disease management through increased research and educational opportunities.
Think NET cancer is rare? There are over 120,000 patients in the US, and 12,000 new cases diagnosed annually.
Patients need to be aware of the treatment options available to them. Nationally known Carcinoid/NET expert Dr. Eugene Woltering explains that “educating neuroendocrine cancer patients is one of the best methods of getting current information into the hands of the medical community.” This concept works. Recently a new patient was diagnosed by a dermatologist because of information given to the physician by a carcinoid cancer survivor.
Maryann Wahmann, VP of CCAN and herself a carcinoid cancer survivor tells us that, “These events definitely save lives! My husband and I went to our first patient conference in 2003 and were absolutely shocked by the information we got there that we didn’t get from our local doctors. Going there saved my life. Because NET cancer has no celebrity spokesperson and little publicity, our researchers get modest funding. Many carcinoid cancer patients go untreated for years or are mis-diagnosed.”
Call CCAN’s office at 866-850-9555 or visit http://www.carcinoidawareness.org for more information.